An Incisive, In-depth Analysis on the Exosome Diagnostic And Therapeutics Market
This study offers a comprehensive, 360 degree analysis on the Exosome Diagnostic And Therapeutics market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Exosome Diagnostic And Therapeutics market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
Top Five Players Account For Over 35% Share of the Exosome Diagnostics and Therapeutics Market
The exosome diagnostics and therapeutics market remains a fragmented landscape. Top five companies collectively represent a significant share in the exosome diagnostics and therapeutics market. These companies include Thermo Fisher Inc., Malvern Instruments, Miltenyi Biotec, Exosome Sciences and Exosome Diagnostics that account for over 35 percent revenue share in exosome diagnostics and therapeutics market.
Market presence of these tier 1 companies is mainly in the United States. Key participants in the exosome diagnostics and therapeutics market are mainly involved in new product launches and acquisitions. In 2017, Exosome Diagnostics launched MedOncAlyzer 170, its biopsy pan-cancer panel that circulates tumor DNA in a single assay. In addition, these players are also involved in collaborations and partnerships with local vendors in a bid to enhance their distribution network.
Favorable Support from Regulatory Bodies to Accelerate Growth
Increasing support from governments and regulatory bodies with respect to funding and research grants continues to influence the growth of exosome diagnostics and therapeutics market. Formulation of policies and subsidy provisions by various governments have encouraged research and development activities in the exosome diagnostics and therapeutics space.
Regulatory bodies have been encouraging development or up gradation of therapeutic devices for efficient treatment of chronic diseases. For instance, Food and Drug Administration (FDA) launched Breakthrough Devices Program in December 2017 to facilitate effective diagnosis of life-threatening diseases. Companies in the exosome diagnostics and therapeutics space are benefitted as they are able to enhance their therapeutic base. Aethlon Medical Inc., under the Breakthrough Devices Program, obtained EAP (Expedited Access Pathway) to push its Hemopurifier system as an effective treatment against fatal viruses.
Exosome Diagnostics and Therapeutics in Drug Delivery to Fight Chronic Conditions
Exosome diagnostics and therapeutics market is largely influenced by the growing potential of exosomes as carriers of functional RNA and proteins. The demand for exosome diagnostics and therapeutics is expected to increase at a significant pace owing to their use in drug delivery field. Several exosome agents are in pipeline that are being evaluated for chronic diseases. For instance, Capricor Therapeutics is assessing exosomes produced by CDCs for treating inflammatory conditions.
In addition, exosome diagnostics and therapeutics companies are focused on tapping exosome diagnostics and therapeutics potential to reduce metastasis. For instance, Aethlon Medical is developing HER2osome device. Use of exosome diagnostics and therapeutics as a potential agent in drug delivery is expected to fuel the growth of exosome diagnostics and therapeutics market in the coming years.
Venture Financing – New Trend in the Exosome Diagnostics and Therapeutics Market
Venture capital firms are investing in the exosome diagnostics and therapeutics market. Growing investments in the exosome diagnostics and therapeutics space are supporting upcoming start-ups in developing their exosome diagnostics and therapeutics platforms. For instance, Google Ventures supported a funding of US$ 45.4 million for exosome diagnostics and therapeutics company – Evox Therapeutics. This trend is likely to offer potential avenues for exosome diagnostics and therapeutics companies in turn supporting the future of exosome diagnostics and therapeutics as a major biotech breakthrough.
Companies involved in the exosome diagnostics and therapeutics market are focusing on launching new exosome diagnostics and therapeutics products. For instance, Exosome Diagnostics Inc., has introduced bladder cancer surveillance panel, an addition in its exosome diagnostics and therapeutics portfolio.
Companies are launching tools and making investments to support exosome diagnostics and therapeutics research. Lonza has carried out huge investments via the acquisition of HansaBiomed Life Sciences in May 2017. Exosome diagnostics and therapeutics companies are also rolling out on conducting new clinical trials by achieving regulatory approvals. For instance, in December 2017, Capricor Therapeutics Inc., achieved clearance from FDA for new clinical trial of CAP-1002. Likewise, in 2018, Aegle gained clearance for its exosome diagnostics and therapeutics clinical trials in humans.
Companies are also involved in acquisitions to enhance their footprint in exosome diagnostics and therapeutics space. For instance, recently, Bio-Techne Corporation acquired Exosome Diagnostics to enhance its leadership in the exosome diagnostics and therapeutics market, particularly in on-invasive liquid biopsy space.
The insightful research report on global exosome diagnostic and therapeutics market provides a comprehensive analysis on every facet of the market along with forecasts. This research report will give the reader an explicit understanding of the global market with which informed decisions can be chalked to stay in pace with the changing market scenario. It will introduce a broad spectrum of several aspects involved along with forecasts thus supporting to detect major revenue pockets.
Portraying a global perspective
The research report on global exosome diagnostic and therapeutics market provides an exhaustive analysis on market shares, demand and supply analysis, sales volume and value analysis of various companies along with segmental analysis, with respect to important geographies of North America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Latin America, Japan and Middle East and Africa (MEA) along with a regional breakdown. These regions are analysed keeping in view several aspects which influence the growth of the global exosome diagnostic and therapeutics market. The report contains an outline of forces which affect the global market scenario. This gives an idea of how to plan market entry strategies, establish connect with the various customers as well as target audience and to establish hold in that area. An unbiased holistic 3600 view of the global exosome diagnostic and therapeutics market is portrayed in the research report which supports the reader in making informed decisions based on strong data analysis and key recommendations.
Understanding the competition
The research report on global exosome diagnostic and therapeutics market covers product portfolios, pipeline analysis of key companies, for instance as big as Thermo Fisher Scientific, their strategies to maintain their present scenario in the market, their global presence and future expansion plans, mergers and acquisitions, distribution channel analysis, pricing analysis, product positioning tactics, etc. An entire section is dedicated to competitive landscape which includes information on the major key players in the global exosome diagnostic and therapeutics market both from the manufacturing side as well as the demand side.
A one-of-its-kind research methodology
A more robust, unique and effective research methodology has been followed by Future Market Insights in crafting the global exosome diagnostic and therapeutics market study which enables a near 100 percent accuracy in all angles. The research process uses primary research, secondary research and expert opinions to get a thorough understanding of the global market. Secondary research is the base of market understanding which is used to obtain a broad view of the market, basis which primary interviews are conducted during which data gleaning starts. Expert opinions are also tabulated and the data is cross verified. Each data point is cross checked and re-evaluated as the primary interview progresses. This enables the analysts to carry out data crunching with optimum accuracy. With this study it is possible to obtain actionable intelligence which delivers value addition to the reader.
By Product Type
By End User
How does this research report add value?
Future Market Insights extends support to organizations by doing all the research weight lifting and coordinating with their research teams to assist them in their tasks and achieve their goals and objectives. Below mentioned are few highlights which would entice you
An unbiased third party opinion is what the research promotes
Actionable intelligence which accompanies at every step
24x7 analyst support to resolve queries or attend any requirement pertaining to respective market along with respective domain experts
A near to 100 percent accuracy in data and statistics
In-depth weighted analysis with a deep dive in the market across several regions with a detailed five level segmentation
Analytically strong ten year forecasts to assist in planning future moves
Covers market controlling aspects, key developments and innovations from strategic and technological standpoints respectively
Exosome Diagnostic And Therapeutics Market Reports - Table of Contents
11. Forecast Factors: Relevance and Impact
12. Forecast Assumptions
19. Research Methodology